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RNA NANOPARTICLE FOR TREATMENT OF 
GASTRIC CANCER 
RELATED APPLICATIONS 
This application is a § 371 National State Application of 
PCT/US2016/021444 filed Mar. 9, 2016 which claims the 
benefit of U.S. Provisional Patent Application No. 62/130, 
527, filed Mar. 9, 2015, the entire disclosure of which are 
hereby incorporated by reference in their entirety. 
GOVERNMENT INTEREST 
This invention was made with govermnent support under 
CA151648 and EB012135 awarded by the National Insti-
tutes of Health. The government has certain rights in the 
invention. 
SEQUENCE LISTING 
The instant application contains a Sequence Listing which 
has been submitted electronically in ASCII format and is 
hereby incorporated by reference in its entirety. Said ASCII 
copy, created on Dec. 20, 2017, is named 2935720-006-US2 
SL.txt and is 5,228 bytes in size. 
TECHNICAL FIELD 
2 
dots (13), folic acid conjugated upper conversion nanopar-
ticles (14), Folate conjugated gold nanorods (15), ce6-
conjugated carbon dots (16), ce6-conjugated Au nanoclus-
ters (Au NCs) (17,18). However, clinical translation of these 
5 prepared nanoprobes still presents great challenge because 
all these prepared nanoprobes are not only distributed to the 
site of gastric cancer, but also partially accumulated in other 
organs. Therefore, the development of safe and effective 
nanoprobes for in vivo targeted delivery, imaging and simul-
10 taneous therapy of early gastric cancer is desirable. 
SUMMARY 
The presently-disclosed subject matter meets some or all 
15 of the above-identified needs, as will become evident to 
those of ordinary skill in the art after a study of information 
provided in this document. 
This Summary describes several embodiments of the 
presently-disclosed subject matter, and in many cases lists 
20 variations and permutations of these embodiments. This 
Summary is merely exemplary of the numerous and varied 
embodiments. Mention of one or more representative fea-
tures of a given embodiment is likewise exemplary. Such an 
embodiment can typically exist with or without the 
25 feature(s) mentioned; likewise, those features can be applied 
to other embodiments of the presently-disclosed subject 
matter, whether listed in this Summary or not. To avoid 
excessive repetition, this Summary does not list or suggest 
The presently-disclosed subject matter relates to RNA 
nano structure molecule and method to treat gastric cancer in 30 
a subject. More particularly, the presently disclosed subject 
matter relates to a RNA nanostructure and composition 
containing a multiple branched RNA nanoparticle, a gastric 
cancer targeting module, and an effective amount of a 
therapeutic agent. Further, the presently disclosed subject 35 
matter relates to a method of using the RNA nanoparticle 
composition to treat gastric cancer in a subject having or at 
risk of having gastric cancer. 
all possible combinations of such features. 
The presently disclosed subject matter in some embodi-
ments relates to an artificial RNA nanostructure molecule. 
The RNA nanostructure molecule includes a multiple 
branched RNA junction motif comprising at least one RNA 
oligonucleotides, and a gastric cancer targeting module 
conjugated to the RNA junction motif. In some embodi-
ments, the RNA nanostructure further includes at least one 
bioactive agent. In some embodiments, the RNA nano struc-
ture binds to gastric cancer cells. A non-limiting example of 
the bioactive agent is a therapeutic agent. In some embodi-
INTRODUCTION 40 ments, the bioactive agent includes drugs, fluorescent dyes, 
or chemicals. In some embodiments, the bioactive agent 
includes an imaging module. Non-limiting examples of the 
imaging module is fluorescent dye, including a non-limiting 
example Alexa647. In some embodiments, the diameter of 
Gastric cancer is the one of the most common cancers, 
and the second leading cause of cancer-related death in the 
world (1,2). The effective treatment remains challenging 
primarily because most diagnosed patients present advanced 
stages of the disease. It remains very difficult to cure 
effectively, primarily because most patients present 
advanced stages of the diseases. Up to date, surgery, radia-
tion and chemotherapies are generally very effective for 
early and in situ gastric cancers, but advanced and metastatic 50 
cases do not respond to chemo- or radiation therapies (3-5) 
and resistance to chemotherapy-induced apoptosis is a major 
cause for the failure of conventional therapies (6-8). The 
current prognosis of gastric cancer is very poor with 5-year 
survivals of less than 24% (9). Therefore, developing novel 55 
strategies and approaches for recognizing, tracking and 
killing gastric cancer cells in early disease stage is urgently 
demand. 
Previously, multifunctional nanoprobes has been studies 
to realize targeted imaging and simultaneous therapy of 
gastric cancer (10,11). The previous studies show that sub-
cutaneous and in situ gastric cancer tissues with 5 mm in 
diameter could be recognized and treated using multifunc-
tional nanoprobes such as BRCAAl (breast cancer associ-
ated antigen 1, AF208045) monoclonal antibody-conjugated 
fluorescent magnetic nanoparticles (12), Her2 monoclonal 
antibody-conjugated RNase-A-associated CdTe quantum 
45 the molecule is at least about 40 nm or less. In some 
embodiments, the molecule has zeta potential ranging from 
about -150 m V to about 150 m V. In some embodiments, the 
molecule has zeta potential ranging from about -125 my to 
about 75 mV. In some embodiments, the molecule is sub-
stantially stable in a pH value ranges from about 2 to about 
13. 
In some embodiments, the nanostructure comprises at 
least one chemical modification at 2' position. Non-limiting 
examples of the chemical modification includes 2'Fluoro, 
2'Amine, and 2'O-Methyl. In some embodiments, the mul-
tiple branched RNA comprises sequence 5'-CCA-
CAUAAAGGGCCCACUAuuCCCACAUACUUU-
GUUGAUCC-3' (SEQ ID NO: 4). In some embodiments, 
the multiple branched RNA includes sequence 
60 5'-UAGUGGGCCCUUUAUGUGG-3' (SEQ ID NO: 5). 
In some embodiments, the multiple branched RNA junc-
tion motif is a three-branched RNA junction motif. In some 
embodiments of the present disclosure, the RNA molecules 
form dimers, trimers, hexamers, and patterned superstruc-
65 tures. Further, In some embodiments, a branch of the three-
branched RNA junction motif includes an a3WJ RNA 
module (SEQ ID NO: 1); a b3WJ RNA module (SEQ ID 
US 10,781,446 B2 
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NO: 2); or a c3WJ RNA module (SEQ ID NO: 3). In one 
embodiment, the three-branched RNA junction motif com-
prises an a3WJ RNA module (SEQ ID NO: 1); a b3WJ RNA 
module (SEQ ID NO: 2); and a c3WJ RNA module (SEQ ID 
NO: 3). The SEQ ID NO: 1 includes nucleotide sequence 5 
5'-UUG CCA UGU GUA UGU GGG-3', the SEQ ID NO: 2 
comprises nucleotide sequence 5'-CCC ACA UAC UUU 
GUU GAUCC-3', and the SEQ ID NO: 3 comprises nucleo-
tide sequence 5'-GGA UCAAUC AUG GCAA-3'. 
In some embodiments, the gastric cancer targeting mod- 10 
ule includes a ligand that binds to at least one gastric cancer 
cell surface marker. In some embodiments, the ligand binds 
to a folate receptor, an epidermal growth factor receptor 2 
(ErbB-2/HER2), an epidermal growth factor receptor 
15 
(EGFR), a HER2 or a combination thereof. In some embodi-
ments, the ligand is an aptamer. Non-limiting examples of 
the aptamer are aptamers binding to EGFR, PDGFR, folate 
receptor, or a combination thereof. In one example, the 
ligand is a EGFR targeting aptamer. In one example, the 20 
ligand has sequence 5'-G CCU UAG UAA CGU GCU UUG 
AUG UCG AUU CGA CAG GAG GC 3' (SEQ ID NO: 6). 
In some embodiments, the targeting module is a folate. 
Non-limiting examples of folate are folic acid, 5-methyltet-
rahydro folate, 5-formyltetrahydrofolate, dihydrofolate, tet- 25 
rahydrofolate, or a combination thereof. 
In some embodiments, the bioactive agent is a drug, a 
fluorescent dye, a chemical, or a combination thereof. In 
some embodiments, wherein the bioactive agent is a siRNA, 
a miRNA, an anti-mRNA, a ribozyme RN As, or an antisense 30 
RNAs. In some embodiments, the bioactive agent is directed 
a gastric cancer marker. In some embodiments, the bioactive 
agent is a siRNA sequence. Non-limiting examples of the 
siRNA are siRNA is directed to Survivin, Bcl-2, XIAP, 
BCL-XL, or BRCAAl. Non-limiting examples of the 35 
siRNA include siRNA sequence 5' GGACCACCGCAUCU-
CUACAdTdT 3' (SEQ ID NO: 7), 5' dTdTCCUGGUG-
GCGUAGAGAUGU 3' (SEQ ID NO: 8), 5'-AAGCUGu-
CACAGAGGGGCUAC-3' (SEQ ID NO: 9), 
5'GUAGCCCCUCUGUGACAGCUU-3 (SEQ ID NO: 10), 40 
5'-CCAUGUGCUAUACAGUCAUUACUUU-3' (SEQ ID 
NO: 11 ), 5'-AAAGUAAUGACUGUAUAGCACAUGG-3' 
(SEQ ID NO: 12), 5'-UUGGACAAUGGACUGGUUGA-3' 
(SEQ ID NO: 13), or 5'-UCAACCAGUCCAUUGUC-
CAA-3 (SEQ ID NO: 14). In one embodiment, siRNA is a 45 
BRCAAl siRNA. A non-limiting example is a siRNA 
sequence 5'-CCACAUAAAGGGCCCACUA-3' (SEQ ID 
NO: 15). Another non-limiting example is a siRNA 
sequence 5'-UAGUGGGCCCUUUAUGUGG-3' (SEQ ID 
NO: 5). In some embodiments, the bioactive agent is a 50 
microRNA sequence. In some embodiments, the bioactive 
agent is an anti-miRNA molecule for a miRNA comprising 
miR-9, miR-l0b, miR-21, or miR-26. In some embodi-
ments, the bioactive agent is a miRNA molecule for a 
miRNA comprising let-7a, miR-l0b, miR-25, miR-34a, 55 
miR-124, miR-145, or miR-181b. 
Further provided, in some embodiments of the presently 
disclosed subject matter, is a composition including a thera-
peutically effective amount of the RNA nano structure mol-
ecule as disclosed above and herein. In some embodiments, 60 
the composition further includes a pharmaceutically accept-
able carrier. 
4 
Yet further provided in some embodiments, is a method of 
treating gastric cancer in a subject having or at risk of having 
gastric cancer. The method includes the step of administer-
ing to the subject a therapeutically effective amount of a 
composition comprising the RNA nano structure molecule as 
disclosed above and herein. In some embodiments, the 
method includes a composition further including a pharma-
ceutically acceptable carrier. In some embodiments, the 
subject is a mammal or a non-mammal vertebrate. In some 
embodiments, the subject is a human. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIGS. lA and 1B include diagrams and images illustrat-
ing the global structure of the therapeutic RNA nanoparticles 
with BRCAAl siRNA. FIG. lA is the design of the RNA 
nanoparticles (SEQ ID NOS 1, 16, 3 and 4, respectively, in 
order of appearance). Left is the one use in animal trial. 
Right is the extended one to prepare the AFM images. FIG. 
1B is the AFM image of extended 3WJ RNA nanoparticles. 
The RNA complex in left of a is estimated to be around 10 
nm. Due to convolution of the tip size HO nm in diameter) 
in AFM images, features smaller than the size of the tip 
carmot be resolved. To characterize the structure of the RNA 
constructs, the 3WJ nanoparticles were extended by 39-60 
base-pairs (in red color), which is within the persistence 
length of dsRNA and will not affect the 3WJ folding as 
described before (31 ), to generate the AFM image as shown. 
FIG. 2 includes graphs showing flow cytometry analysis 
for specific binding of 3WJ-FA-A647 nanoparticles to 
MGC803 cells (left, folate positive), GES-1 cells (right, 
folate negative control). 
FIG. 3 shows the BRCAAl silencing effects of 
FA-pRNA-3WJ-BRCAAlsiRNA assayed by (a) qRT-PCR 
(GAD PH is the endogenous control) (there existed statistical 
difference between FA-pRNA-3WJ-BRCAAlsiRNA group 
and FA-pRNA-3WJ-Scramb-siRNA group, P<0.01) and (b) 
western blot assay (~-actin bands served as loading control). 
FIG. 4 is a graph showing inhibition of the growth of 
MGC803 cells by the nanoparticle of FA-pRNA-3WJ-
BRCAAlsiRNA using CCK8 (Cell Counting Kit-8) assays. 
The "Control" is non-treated MGC803 cells. 
FIG. 5 includes graphs showing determination of cell 
death by flow cytometry of Annexin V-FITC/PI staining in 
MGC803 cells transfected with 25 nM FA-pRNA-3WJ-
BRCAAlsiRNA or FA-pRNA-3WJ-Scram-siRNA for 48 h. 
FIG. 6A includes images showing representative in vivo 
fluorescence images of MGC803-tumour-bearing mouse 
after iv-injected with FA-AlexaFluor647-labeled pRNA 
nanoparticle. The tumor areas are indicated with arrows. 
FIG. 6B shows representative ex vivo images of tumors and 
organs. Labels: 1, tumor; 2, heart; 3, liver; 4, spleen; 5, lung; 
6, Stomach; 7, kidneys; 8, bladder; 9, muscle. FIG. 6C is a 
graphs showing the average fluorescence intensities from the 
tumor areas of post-injection (3 mice per time point). The 
error bars represent SEM (n=3). 
FIG. 7 includes images showing tumor sizes in test group 
and control group under different days FIG. 7 A is an image 
showing 0 day at un-treated mouse; FIG. 7B is an image 
showing Oday in un-treated mouse; FIG. 7C shows 14 days 
at control mouse; FIG. 7D is an image showing 14 days in 
test mouse, and FIG. 7E shows tumor tissues from experi-
Still further, the presently disclosed subject matter in 
some embodiments provides a nanoparticle delivery system 
including a RNA nano structure molecule as disclosed above 
and herein. In some embodiments, the delivery system 
further includes a pharmaceutically acceptable carrier. 
65 ment. 
FIG. 8 is a graph showing the tumor size curve as the 
post-treatment time increases. There existed statistical dif-
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ference between FA-pRNA-3WJ-BRCAAlsiRNA treated 
group and FA-pRNA-3WJ-Scram-siRNA treated group, 
P<0.01. 
6 
such publicly-available databases are references to the most 
recent version of the database as of the filing date of this 
Application. 
FIG. 9 includes images showing the result of HE immu-
nostaining of important organs showing the undetectable 5 
damage. 
While the terms used herein are believed to be well 
understood by one of ordinary skill in the art, definitions are 
set forth to facilitate explanation of the presently-disclosed 
subject matter. FIG. 10 is an images showing the expression of related 
apoptosis proteins of MGC803 cells at 48 h post-treatment 
by Western blotting. 1: scrambled control; 2: FA-Alex-
aFluor647-labeled pRNA nanoparticle; 3: control. 10 
Unless defined otherwise, all technical and scientific 
terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which the 
presently-disclosed subject matter belongs. Although any 
FIG. 11 is a diagram showing the potential mechanism of 
RNA nanoparticles for gastric cancer therapy. 
FIG. 12A is an graph showing the size of 3WJ-BRCAA1 
siRNA nanoparticle. FIG. 12B is a graph showing the zeta 
15 
potential of 3WJ-BRCAA1 siRNA nanoparticle. The RNA 
nanoparticles were dissolved in 1 xTMS buffer with concen-
tration at 1.5 µM and then were measured by Zetasizer 
nano-ZS (Malvern Instrument). The data showed that the 
size of the nanoparticle is 5.20±0.83 nm in diameter, and the 20 
zeta potential is -16.57±0.75 my, as shown in Figure SIA 
and SIB. The data were obtained from three independent 
measurements. 
methods, devices, and materials similar or equivalent to 
those described herein can be used in the practice or testing 
of the presently-disclosed subject matter, representative 
methods, devices, and materials are now described. 
Following long-standing patent law convention, the terms 
"a", "an", and "the" refer to "one or more" when used in this 
application, including the claims. Thus, for example, refer-
ence to "a cell" includes a plurality of such cells, and so 
forth. 
Unless otherwise indicated, all numbers expressing quan-
tities of ingredients, properties such as reaction conditions, 
and so forth used in the specification and claims are to be 
understood as being modified in all instances by the term FIG. 13 includes a graph and an image showing the effects 
of pH on the fluorescent intensity and stability of RNA 
nanoparticles. FIG. 13A is a graphs illustrating the effects of 
pH (pH 2 to 13) on the fluorescent intensity of RNA 
nanoparticles by PerkinElmer LS 55 spectrofluorimeter, and 
FIG. 13B is an image showing the effects of pH (pH 2 to 13) 
25 "about". Accordingly, unless indicated to the contrary, the 
numerical parameters set forth in this specification and 
claims are approximations that can vary depending upon the 
desired properties sought to be obtained by the presently-
disclosed subject matter. 
on the stability of RNA nanoparticles examined by 1.2% 30 
agarose gel electrophoresis. 
As used herein, the term "about," when referring to a 
value or to an amount of mass, weight, time, volume, 
concentration or percentage is meant to encompass varia-
tions of in some embodiments ±20%, in some embodiments 
±10%, in some embodiments ±5%, in some embodiments 
FIG. 14 is a graphs showing the determination of the 
melting temperature of the 3WJ-BRCAA1 siRNA nanopar-
ticle. 
FIG. 15 is an image showing the effects of RN Aase A on 
the stability ofRNAnanoparticles. Lane 1: 10 U RNAaseA; 
Lane2: 50 U RNAaseA, Lane 3: 100 U RNAaseA, Lane 4: 
500 U RNAase A; Lane 5: 1000 U RNAase A; Lane 6: 
10000 U RN Aase A. RNA nanoparticles on different lanes 
exhibited identical position, similar brightness and no obvi-
ous degradation, suggesting that prepared RNA nanopar-
ticles have good stability against RNase A (less than 10000 
U)-mediated degradation. 
FIG. 16 is a graph showing light scattering plots of 
MGC803 cells at 48 h treated with FA-pRNA-3WJ-BR-
CAAl-siRNA nanoparticles. 
DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
The details of one or more embodiments of the presently-
disclosed subject matter are set forth in this document. 
Modifications to embodiments described in this document, 
and other embodiments, will be evident to those of ordinary 
skill in the art after a study of the information provided in 
this document. The information provided in this document, 
and particularly the specific details of the described exem-
plary embodiments, is provided primarily for clearness of 
understanding and no unnecessary limitations are to be 
understood therefrom. 
In certain instances, nucleotides and polypeptides dis-
closed herein are included in publicly-available databases, 
such as GENBANK® and SWISSPROT. Information 
including sequences and other information related to such 
nucleotides and polypeptides included in such publicly-
available databases are expressly incorporated by reference. 
Unless otherwise indicated or apparent the references to 
35 ±1 %, in some embodiments ±0.5%, and in some embodi-
ments ±0.1 % from the specified amount, as such variations 
are appropriate to perform the disclosed method. As used 
herein, ranges can be expressed as from "about" one par-
ticular value, and/or to "about" another particular value. It is 
40 also understood that there are a number of values disclosed 
herein, and that each value is also herein disclosed as 
"about" that particular value in addition to the value itself. 
For example, if the value "10" is disclosed, then "about 10" 
is also disclosed. It is also understood that each unit between 
45 two particular units are also disclosed. For example, if 10 
and 15 are disclosed, then 11, 12, 13, and 14 are also 
disclosed. 
The presently disclosed subject matter in some embodi-
ments relates to an artificial RNA nanostructure molecule. 
50 The RNA nanostructure molecule includes a multiple 
branched RNA junction motif comprising at least one RNA 
oligonucleotides, and a gastric cancer targeting module 
conjugated to the RNA junction motif. In some embodi-
ments, the RNA oligonucleotides is at least 6 nucleotides in 
55 length. In some embodiments, the RNA nanostructure fur-
ther includes at least one bioactive agent. In some embodi-
ments, the RNA nanostructure binds to gastric cancer cells. 
A non-limiting example of the bioactive agent is a thera-
peutic agent. In some embodiments, the bioactive agent 
60 includes drugs, fluorescent dyes, or chemicals. In some 
embodiments, the bioactive agent includes an imaging mod-
ule. Non-limiting examples of the imaging module is fluo-
rescent dye, including a non-limiting example Alexa647. In 
some embodiments, the nanostructure comprises at least one 
65 chemical modification at 2' position. Non-limiting examples 
of the chemical modification includes 2'Fluoro, 2'Amine, 
and 2'O-Methyl. In some embodiments, the multiple 
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branched RNA comprises sequence 5'-CCA-
8 
module (SEQ ID NO: 1); a b3WJ RNA module (SEQ ID 
NO: 2); or a c3WJ RNA module (SEQ ID NO: 3). In one 
embodiment, the three-branched RNA junction motif com-
prises an a3WJ RNA module (SEQ ID NO: 1); a b3WJ RNA 
CAUAAAGGGCCCACUAuuCCCACAUACUUU-
GUUGAUCC-3' (SEQ ID NO: 4). In some embodiments, 
the multiple branched RNA includes sequence 
5'-UAGUGGGCCCUUUAUGUGG-3' (SEQ ID NO: 5). 5 module (SEQ ID NO: 2); and a c3WJ RNA module (SEQ ID 
NO: 3). The SEQ ID NO: 1 includes nucleotide sequence 
5'-UUG CCA UGU GUA UGU GGG-3', the SEQ ID NO: 2 
comprises nucleotide sequence 5'-CCC ACA UAC UUU 
GUU GAUCC-3', and the SEQ ID NO: 3 comprises nucleo-
The term "RNA" refers to a molecule comprising at least 
one ribonucleotide residue. By "ribonucleotide" is meant a 
nucleotide with a hydroxyl group at the 2' position of a 
~-D-ribofuranose moiety. The terms encompass double 
stranded RNA, single stranded RNA, RNAs with both 
double stranded and single stranded regions, isolated RNA 
such as partially purified RNA, essentially pure RNA, 
synthetic RNA, recombinantly produced RNA, as well as 
altered RNA, or analog RNA, that differs from naturally 
occurring RNA by the addition, deletion, substitution, and/or 15 
alteration of one or more nucleotides. Such alterations can 
include addition of non-nucleotide material, such as to the 
end( s) of an siRNA or internally, for example at one or more 
nucleotides of the RNA. Nucleotides in the RNA molecules 
10 tide sequence 5'-GGA UCA AUC AUG GCA A-3'. 
In some embodiments, the diameter of the molecule is at 
least about 40 nm or less. The diameter is at least about 35 
nm or less, at least about 30 nm or less, at least about 25 nm 
or less, at least 20 nm or less, at least 15 nm or less, at least 
10 nm or less, at least 5 nm or less. 
In some embodiments, the molecule has zeta potential 
ranging from about -150 mV to about 150 mV. The RNA 
molecule has a zeta potential ranging from about -140 mV 
to about 140 mV, from about -130 mV to about 130 mV, 
of the presently disclosed subject matter can also comprise 
non-standard nucleotides, such as non-naturally occurring 
nucleotides or chemically synthesized nucleotides or deoxy-
nucleotides. These altered RNAs can be referred to as 
20 from about -120 m V to about 120 m V, from about -110 m V 
to about 110 m V, from about -100 m V to about 100 m V, 
from about -90 to about 90 m V, form about -80 m V to about 
80 m V, from about - 70 m V to about 70 m V, from about -60 
analogs or analogs of a naturally occurring RNA. 
As disclosed herein, RNA nanotechnology has recently 25 
emerged as an important field due to recent finding of its 
high thermodynamic stability, favorable and distinctive in 
vivo attributes (US 2014/0179758, hereby incorporate by 
reference in its entirety). In some embodiments of the 
present disclosure, as disclosed in US2014/0179758, the 30 
RNA molecules form dimers, trimers, hexamers, and pat-
terned superstructures. Further, RNA nanoparticles can be 
fabricated with precise control of shape, size and stoichi-
ometry, as demonstrated by the packaging RNA (pRNA) of 
the bacteriophage phi29 DNA packaging motor, which 35 
forms dimmers, trimers, and hexamers via hand-in-hand 
interactions of the interlocking loops (27,28). The pRNA 
contains an ultra-stable three-way junction (3WJ) motif 
(29-31 ), which can be assembled from three short fragments 
with extremely high affinity. Recently, the crystal structure 40 
of the pRNA-3WJ motif was obtained (32) and a variety of 
therapeutic RNA nanoparticles using the pRNA-3WJ and 
pRNA-X motifs as scaffolds have been constructed (33-34). 
The pRNA-3WJ nanoparticles display thermodynamically 
stable properties, including high melting temperature with 45 
low free energy, resistance to denaturation in SM urea, and 
resistance to dissociation at very low concentrations in the 
blood. Boiling resistant RNA nanoparticles with controllable 
shapes and defined stoichiometry have recently been 
reported (36). Various imaging groups, such as fluorophores; 50 
targeting ligands, such as receptor binding aptamers; and 
therapeutic modules, such as siRNA, miRNA or ribozymes 
can be integrated into the 3WJ scaffold without affecting the 
folding and functionality of the core motif and incorporated 
functional moieties. Upon 2'-Fluoro (2'-F) modifications of 55 
Uracil (U) and Cytosine (C) nucleotides, the RNA nanopar-
ticles become resistant to RNase degradation with enhanced 
in vivo half-life while retaining authentic functions of the 
incorporated modules. Furthermore, the pRNA nanopar-
ticles are non-toxic, non-immunogenic, and display favor- 60 
able biodistribution and pharmacokinetic profiles in mice. 
In some embodiments, the multiple branched RNA junc-
tion motif is a three-branched RNA junction motif. In some 
embodiments of the present disclosure, the RNA molecules 
form dimers, trimers, hexamers, and patterned superstruc- 65 
tures. Further, In some embodiments, a branch of the three-
branched RNA junction motif includes an a3WJ RNA 
m V to about 60 m V, from about -50 m V to about 50 m V. 
The molecule has a zeta potential ranging from about -40 
my to about 40 mV, from about -30 mV to about 30 mV, 
from about -20 m V to about 20 m V, from about -10 m V to 
about 10 mV. 
In some embodiments, the molecule is substantially stable 
in a pH value ranges from about 2 to about 13. The RNA 
molecule is substantially stable in pH about 2, 3, 4, 5, 6, 7, 
8, 9, 10, 11, 12 and 13. As used herein, the term "substan-
tially stable" can refer to physical and/or chemical stability. 
As will be recognized by those of ordinary skill in the art, 
the term "substantially stable" can refer to stability of the 
composition under certain conditions, relative to an initial 
composition (i.e., when a particular batch of the composition 
is initially prepared). In this regard, as will be recognized by 
those of ordinary skill in the art, one manner in which 
stability of a particular embodiment of the composition can 
be determined is as follows: preparing a batch of the 
embodiment of the composition, making an initial assess-
ment of a sample of the composition ( control sample), 
subjecting a sample of the composition to conditions of 
interest (e.g., storage at a particular temperature for a 
particular time period) (test sample), making an assessment 
of the test sample, and comparing the assessment of the 
control sample to the assessment of the test sample. Calcu-
lations can be made to determine whether the amounts 
present in the test sample are 100%±20, 19, 18, 17, 16, 15, 
14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, 0.5, or 0.1 % of the 
amount that is in the control sample. 
In some embodiments, the RNA nanostructure includes a 
gastric cancer targeting module. In some embodiments, the 
gastric cancer targeting module includes a ligand that binds 
to at least one gastric cancer cell surface marker. In some 
embodiments, the ligand binds to a folate receptor, an 
epidermal growth factor receptor 2 (ErbB-2/HER2), an 
epidermal growth factor receptor (EGFR), a HER2 or a 
combination thereof. In some embodiments, the ligand is an 
aptamer. The term "aptamer" as used herein refers to an 
oligonucleotide that can bind specifically to its target with 
high affinity. Non-limiting examples of the aptamer are 
aptamers binding to EGFR, PDGFR, folate receptor, or a 
combination thereof. In one example, the ligand is a EGFR 
targeting aptamer. In one example, the ligand has sequence 
5'-G CCU UAG UAA CGU GCU UUG AUG UCG AUU 
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CGA CAG GAG GC 3' (SEQ ID NO: 6). In some embodi-
ments, the targeting module is a folate. 
The term "folate" as used herein can comprise a genus of 
well-defined B-vitamin compounds, including but not lim-
ited to, 5-methyltetrahydro folate, 5-formyltetrahydrofolate, 5 
dihydrofolate, tetrahydrofolate, folic acid and other folate 
compounds. As disclosed herein, the targeted delivery sys-
tems call for a ligand-receptor pair that is specifically found 
in cancer cells. Many, but not all, cancer cells, including 
stomach, ovary, lung, breast, kidney, endometrium, colon 10 
and hematopoietic cells, over-expressed folate receptors 
(FRs) than normal cells for high uptake of folate, since folate 
is essential component during DNA replication and meth-
ylation in highly proliferating cells. Folic acid (FA), a 
synthetic oxidized form offolate, has been widely used as a 15 
ligand conjugate in various cancer targeting materials. 
In some embodiments, the bioactive agent is a drug, a 
fluorescent dye, a chemical, or a combination thereof. In 
some embodiments, wherein the bioactive agent is a siRNA, 
a miRNA, an anti-mRNA, a ribozyme RN As, or an antisense 20 
RNAs. In some embodiments, the bioactive agent is directed 
10 
allow one to accurately identify and determine the future 
course of the disease, respectively. Non-limiting examples 
of gastric cancer biomarkers are described in 
WO2012167112 (herein incorporated by reference in its 
entirety). 
The terms "small interfering RNA", "short interfering 
RNA", "small hairpin RNA", "siRNA", and shRNA are 
used interchangeably and refer to any nucleic acid molecule 
capable of mediating RNA interference (RNAi) or gene 
silencing. See e.g., Bass, Nature 411 :428-429, 2001; 
Elbashir et al., Nature 411 :494-498, 2001a; and PCT Inter-
national Publication Nos. WO 00/44895, WO 01/36646, 
WO 99/32619, WO 00/01846, WO 01/29058, WO 
99/07409, and WO 00/44914. In one embodiment, the 
siRNA comprises a double stranded polynucleotide mol-
ecule comprising complementary sense and antisense 
regions, wherein the antisense region comprises a sequence 
complementary to a region of a target nucleic acid molecule 
(for example, a nucleic acid molecule encoding Survivin). In 
another embodiment, the siRNA comprises a single stranded 
polynucleotide having self-complementary sense and anti-
sense regions, wherein the antisense region comprises a 
sequence complementary to a region of a target nucleic acid 
molecule. In another embodiment, the siRNA comprises a 
a gastric cancer marker. In some embodiments, the bioactive 
agent is a siRNA sequence. Non-limiting examples of the 
siRNA are siRNA is directed to Survivin, Bcl-2, XIAP, 
BCL-XL, or BRCAAl. 25 single stranded polynucleotide having one or more loop 
structures and a stem comprising self complementary sense 
and antisense regions, wherein the antisense region com-
prises a sequence complementary to a region of a target 
In some embodiments of the present disclosure, a RNA 
nanotechnology approach is adopted to overcome some of 
the aforementioned challenges, and report the strategy to 
target and deliver therapeutic BRCAAl siRNA to in vivo 
stomach cancer tissues using FA-conjugated pRNA-3WJ 30 
nanoparticles. The present disclosure relates to the construc-
tion of multi-functional, thermodynamically and chemically 
stable RNA nanoparticles harboring sequences that allow 
specific binding to stomach cancer specific cell surface 
antigens or receptors resulting in the internalization of RNA 35 
nanoparticles into target cells and delivery of the siRNA, 
miRNA, and drugs for attaining synergistic effects for the 
treatment of stomach cancer. Further, the present disclosure 
relates to effects of prepared RNA nanoparticles on the 
regression of gastric cancer tissues in vivo, and potential 40 
molecular mechanism. 
It has been proposed for long time that the RNAi can be 
applied for potential cancer treatment strategy. However, 
lacking of effect delivery system, the therapeutic small 
RNAs including siRNAs, miRNAs, anti-sense RNAs, etc., 45 
remain undrugable. The RNA nanoparticle-based nano-de-
livery platform can overcome aforementioned limitations 
for conventional cancer therapeutic and opens new oppor-
tunities for specific delivering RNAi therapeutics to gastric 
cancer without damaging healthy organs and tissues, reduc- 50 
ing the toxicity and side effects, improving the therapeutic 
effects, and exhibiting great potential in clinical cancer 
therapy. 
The phrase "gastric cancer marker" as used herein refers 
to genes or gene products ( e.g., RNA molecules or proteins) 55 
which are characteristic of some or all of the cells in gastric 
cancer. A gastric cancer marker with diagnostic value can be 
a gene or gene product expressed in normal, non-cancerous 
cells, but is characteristic of a type or classification of cancer 
by, for example, its over-expression or under-expression as 60 
compared to its expression in normal, non-cancerous cells. 
A gastric cancer marker with prognostic value is a gene or 
gene product for which the over-expression or under-ex-
pression confers predictive information about the future 
aggressiveness of a cancer and/or its response to therapy at 65 
the time of diagnosis. In a cancer sample, the patterns of 
expression of diagnostic and prognostic cancer markers 
nucleic acid molecule, and wherein the polynucleotide can 
be processed either in vivo or in vitro to generate an active 
siRNA capable of mediating RN Ai. As used herein, siRNA 
molecules need not be limited to those molecules containing 
only RNA, but further encompass chemically modified 
nucleotides and non-nucleotides. 
In some embodiments, the presently disclosed subject 
matter takes advantage of the ability of short, double 
stranded RNA molecules to cause the down regulation of 
cellular genes, a process referred to as RNA interference. As 
used herein, "RNA interference" (RNAi) refers to a process 
of sequence-specific post-transcriptional gene silencing 
mediated by a small interfering RNA (siRNA). See Fire et 
al., Nature 391:806-811, 1998 and U.S. Pat. No. 6,506,559, 
each of which is incorporated by reference herein in its 
entirety. The process of post-transcriptional gene silencing is 
thought to be an evolutionarily conserved cellular defense 
mechanism that has evolved to prevent the expression of 
foreign genes (Fire, Trends Genet 15:358-363, 1999). 
Disclosed herein are examples of siRNA including Sur-
vivin-specific, Bcl-2, XIAP, and BCL-XL siRNA sequences. 
The Survivin-specific siRNA includes sense sequence: 5' 
GGACCACCGCAUCUCUACAdTdT 3' (SEQ ID NO: 7) 
and antisense sequence: 5' dTdTCCUGGUGGCGUAGA-
GAUGU 3' (SEQ ID NO: 8) (See, e.g., Cancer Gene Ther. 
2004 March; 11(3):186-93. Knockdown of survivin expres-
sion by small interfering RNA reduces the clonogenic sur-
vival of human sarcoma cell lines independently of p53.); 
the Bcl-2 siRNA includes sense sequence: 5'-AAGCUGu-
CACAGAGGGGCUAC-3' (SEQ ID NO: 9), and antisense 
sequence: 5'-GUAGCCCCUCUGUGACAGCUU-3 (SEQ 
ID NO: 10) (See, e.g., Nucleic Acids Res. 2012 July; 
40(13):6319-37. doi: 10.1093/nar/gks294. Epub 2012 Mar. 
30. Delivery of chemo-sensitizing siRNAs to HER2+-breast 
cancer cells using RNA aptamers.); XIAP siRNA includes 
sense sequence: 5'-CCAUGUGCUAUACAGUCAUUAC-
UUU-3 (SEQ ID NO: 11), and antisense sequence: 
5'-AAAGUAAUGACUGUAUAGCACAUGG-3 (SEQ ID 
NO: 12) (See, e.g., Mal Cancer. 2006 Sep. 5; 5:34. Specific 
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rescues down-regulated cancer suppressive miRNAs, where 
the RNA nanostructure introduces cancer suppressive miR-
NAs, including but not limited to, let-7a, miR-l0b, miR-25, 
miR-34a, miR-124, miR-145, and miR-181b. Further 
5 examples is disclosed in US20140045709, which herein 
incorporate by reference in its entirety. 
down-regulation of XIAP with RNA interference enhances 
the sensitivity of canine tumor cell-lines to TRAIL and 
doxorubicin); and BCL-XL siRNA includes sense sequence: 
5'-UUGGACAAUGGACUGGUUGA-3 (SEQ ID NO: 13), 
antisense sequence: 5'-UCAACCAGUCCAUUGUCCAA-3 
(SEQ ID NO: 14) (See, e.g., Acta Biochim Biophys Sin 
(Shanghai). 2005 August; 37(8):555-60. Silencing of Bel-
XL expression in human MGC-803 gastric cancer cells by 
siRNA.) Further, in one embodiment, siRNA is a BRCAAl 
siRNA. A non-limiting example is a siRNA sequence 10 
5'-CCACAUAAAGGGCCCACUA-3' (SEQ ID NO: 15). 
Another non-limiting example is a siRNA sequence 
5'-UAGUGGGCCCUUUAUGUGG-3' (SEQ ID NO: 5). 
In some embodiments, the bioactive agent is a microRNA 
sequence. The term "Micro RN As (miRNAs )" as used herein 15 
are single-stranded, or double stranded non-coding RN As, at 
least about 6 nucleotide in length that can regulate gene 
expression at the post-transcriptional level by either degrad-
ing their target mRNAs or inhibiting their translation (1,2). 
MiRNAs play important roles in regulating cell cycle, 20 
proliferation, differentiation, metabolism, and apoptosis (1). 
The presently disclosed subject matter further provide a 
composition including a therapeutically effective amount of 
the RNA nanostructure molecule as disclosed above and 
herein. In some embodiments, the composition further 
includes a pharmaceutically acceptable carrier. 
The presently disclosed subject matter in some embodi-
ments provides a nanoparticle delivery system including a 
RNA nano structure molecule as disclosed above and herein. 
In some embodiments, the delivery system further includes 
a pharmaceutically acceptable carrier. 
The term "pharmaceutically acceptable carrier" as used 
herein refers to a diluent, adjuvant, excipient, or vehicle with 
which a heterodimeric probe of the disclosure is adminis-
tered and which is approved by a regulatory agency of the 
federal or a state government or listed in the U.S. Pharma-
copeia or other generally recognized pharmacopeia for use 
in animals, and more particularly in humans. Such pharma-
ceutical carriers can be liquids, such as water and oils, 
including those of petroleum, animal, vegetable, or synthetic 
origin, such as peanut oil, soybean oil, mineral oil, sesame 
oil, and the like. The pharmaceutical carriers can be saline, 
gum acacia, gelatin, starch paste, talc, keratin, colloidal 
silica, urea, and the like. When administered to a patient, the 
A compendium of microRNA and respective microRNA 
binding sequences is available at the miRNA registry. (See, 
e.g., Griffiths-Jones et al. (2006) Nucl. Acids Res. 34:D140-
D144; US20140045709, herein incorporate by reference in 25 
their entireties.) In particular embodiments, the microRNA 
and microRNA binding sequence employed in the present 
assay are associated with a disease or condition, wherein an 
antagonist or agonist to the microRNA would be useful in 
preventing or treating the disease or condition. 30 heterodimeric probe and pharmaceutically acceptable carri-
ers can be sterile. Water is a useful carrier when the 
heterodimeric probe is administered intravenously. Saline 
solutions and aqueous dextrose and glycerol solutions can 
In some embodiments, the present disclosure provides 
inhibitors of miRNAs (e.g., anti-miR-21). Compositions 
comprising such inhibitors and methods for inhibiting miR-
21 using such inhibitors are also disclosed herein. Any 
miRNA inhibitor may be used alone, or with other miRNA 35 
inhibitor(s) known in the art. In some embodiments, the 
miRNA inhibitor comprises an antisense molecule. In some 
embodiments, the antisense molecule could be a single or a 
double stranded sequence. Examples of antisense molecule 
include, but are not limited to, siRNAs, triple-helix-forming 40 
agents, ribozymes, RNAi, synthetic peptide nucleic acids 
(PNAs), antigenes (agRNAs), LNA/DNAcopolymers, small 
molecule chemical compounds, and antisense oligonucle-
otides. 
also be employed as liquid carriers, particularly for inject-
able solutions. Suitable pharmaceutical carriers also include 
excipients such as glucose, lactose, sucrose, glycerol monos-
tearate, sodium chloride, glycerol, propylene, glycol, water, 
ethanol, and the like. The present compositions, if desired, 
can also contain minor amounts of wetting or emulsifying 
agents, or pH buffering agents. The present compositions 
advantageously may take the form of solutions, emulsion, 
sustained release formulations, or any other form suitable for 
use. 
The term "therapeutically effective amount," as used 
In some embodiments, the microRNA sequence is at least 
6 nucleotide in length. In some embodiments, the miRNA 
molecule or an equivalent, or a mimic thereof is from about 
6 to about 30 nucleotides in length. In some embodiments, 
the miRNA is about 12 to about 30 nucleotides in length. In 
some embodiments, the miRNA is from about 15 to about 28 
nucleotides in length. In some embodiments, the miRNA is 
about 19 to about 25 nucleotides in length. In some embodi-
ments, the miRNA molecule has a length of at least about 6, 
7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 
24, 25, 26, 27, 28, 29, about 30 nucleotides or more. In some 
embodiments, an antagomir of a miRNA molecule is from 
about 6 to about 30 nucleotides in length, from about 10 to 
about 30 nucleotides in length, from about 12 to about 28 
nucleotides in length. In some embodiments, the antagomir 
of a miRNA molecule has a length of at least about 6, 7, 8, 
9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 
25, 26, 27, 28, 29, about 30 nucleotides or more. 
In some embodiments, the miRNA interferes oncogenic 
miRNA to regress cancer growth. The RNA nanostructure 
molecule contains anti-miRNA that silences oncogenic miR-
NAs, including but not limited to, miR-9, miR-l0b, miR-21, 
miR-17, and miR-26. In some embodiments, the miRNA 
45 herein, refers to the amount of a composition containing 
administered to a patient already suffering from a disease, 
condition, or disorder, sufficient to cure or at least partially 
arrest, or relieve to some extent one or more of the symp-
toms of the disease, disorder, or condition being treated. The 
50 effectiveness of such compositions depend upon conditions 
including, but not limited to, the severity and course of the 
disease, disorder, or condition, previous therapy, the 
patient's health status and response to the drugs, and the 
judgment of the treating physician. By way of example only, 
55 therapeutically effective amounts may be determined by 
routine experimentation, including but not limited to a dose 
escalation clinical trial. 
The specific therapeutically effective dose level for any 
particular patient will depend upon a variety of factors 
60 including the disorder being treated and the severity of the 
disorder; the specific composition employed; the age, body 
weight, general health, sex and diet of the patient; the time 
of administration; the route of administration; the rate of 
excretion of the specific compound employed; the duration 
65 of the treatment; drugs used in combination or coincidental 
with the specific compound employed and like factors well 
known in the medical arts. For example, it is well within the 
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skill of the art to start doses of a compound at levels lower 
than those required to achieve the desired therapeutic effect 
and to gradually increase the dosage until the desired effect 
14 
module (SEQ ID NO: 1); a b3WJ RNA module (SEQ ID 
NO: 2); or a c3WJ RNA module (SEQ ID NO: 3). In one 
embodiment, the three-branched RNA junction motif com-
is achieved. If desired, the effective daily dose can be 
divided into multiple doses for purposes of administration. 5 
Consequently, single dose compositions can contain such 
amounts or submultiples thereof to make up the daily dose. 
The dosage can be adjusted by the individual physician in 
the event of any contraindications. Dosage can vary, and can 
prises an a3WJ RNA module (SEQ ID NO: 1); a b3WJ RNA 
module (SEQ ID NO: 2); and a c3WJ RNA module (SEQ ID 
NO: 3). The SEQ ID NO: 1 includes nucleotide sequence 
5'-UUG CCA UGU GUA UGU GGG-3', the SEQ ID NO: 2 
comprises nucleotide sequence 5'-CCC ACA UAC UUU 
GUU GAUCC-3', and the SEQ ID NO: 3 comprises nucleo-
tide sequence 5'-GGA UCA AUC AUG GCA A-3'. be administered in one or more dose administrations daily, 10 
for one or several days. Guidance can be found in the 
literature for appropriate dosages for given classes of phar-
maceutical products. In further various aspects, a prepara-
tion can be administered in a "prophylactically effective 
amount"; that is, an amount effective for prevention of a 15 
disease or condition. 
Further, the gastric cancer targeting module includes a 
ligand that binds to at least one gastric cancer cell surface 
marker. In some embodiments, the ligand binds to a folate 
receptor, an epidermal growth factor receptor 2 (ErbB-2/ 
HER2), an epidermal growth factor receptor (EGFR), a 
HER2 or a combination thereof. In some embodiments, the 
Suitable methods for administering to a subject an effec-
tive amount of the composition in accordance with the 
methods of the present disclosure include but are not limited 
to systemic administration, parenteral administration (in- 20 
eluding intravascular, intramuscular, intraarterial adminis-
tration), oral delivery, buccal delivery, subcutaneous admin-
istration, inhalation, intratracheal installation, surgical 
implantation, transdermal delivery, local injection, and 
hyper-velocity injection/bombardment. Where applicable, 25 
continuous infusion can enhance drug accumulation at a 
target site (see, e.g., U.S. Pat. No. 6,180,082). 
ligand is an aptamer. Non-limiting examples of the aptamer 
are aptamers binding to EGFR, PDGFR, folate receptor, or 
a combination thereof. In one example, the ligand is a EGFR 
targeting aptamer. In one example, the ligand has sequence 
5'-G CCU UAG UAA CGU GCU UUG AUG UCG AUU 
CGA CAG GAG GC-3' (SEQ ID NO: 6). In some embodi-
ments, the targeting module is a folate. Non-limiting 
examples of folate are folic acid, 5-methyltetrahydro folate, 
5-formyltetrahydrofolate, dihydrofolate, tetrahydrofolate, or 
a combination thereof. 
The RNA nano structure of the method further includes at 
In some embodiments, the present disclosure provides a 
method of treating gastric cancer in a subject having or at 
risk of having gastric cancer. The method includes the step 30 
of administering to the subject a therapeutically effective 
amount of a composition comprising the RNA nanostructure 
molecule as disclosed above and herein. In some embodi-
ments, the method includes a composition further including 
least one bioactive agent. The bioactive agent is a drug, a 
fluorescent dye, a chemical, or a combination thereof. Fur-
ther, the bioactive agent includes a siRNA, a miRNA, an 
anti-mRNA, a ribozyme RNAs, or an antisense RNAs. In 
some embodiments, the bioactive agent is directed a gastric 
cancer marker. In some embodiments, the bioactive agent is 
a siRNA sequence. Non-limiting examples of the siRNAare 
a pharmaceutically acceptable carrier. In some embodi-
ments, the subject is a manimal or a non-mammal vertebrate. 
In some embodiments, the subject is a human. More spe-
cifically, in the method, the RNA nanostructure molecule 
includes a multiple branched RNA junction motif compris-
ing at least one RNA oligonucleotides, and a gastric cancer 
targeting module conjugated to the RNA junction motif. In 
some embodiments of the method, the RNA nanostructure 
further includes at least one bioactive agent. The RNA 
nanostructure binds to gastric cancer cells. A non-limiting 
example of the bioactive agent is a therapeutic agent. The 
bioactive agent includes drugs, fluorescent dyes, or chemi-
cals. In some embodiments, the bioactive agent includes an 
imaging module. In some embodiment of the method, the 
diameter of the RNA molecule is at least about 40 nm or less, 
the molecule has zeta potential ranging from about -150 m V 
to about 150 mV, and the molecule is substantially stable in 
a pH value ranges from about 2 to about 13. In some 
embodiments of the method, the nano structure comprises at 
least one chemical modification at 2' position. Non-limiting 
examples of the chemical modification includes 2'Fluoro, 
2'Amine, and 2'O-Methyl. In some embodiments, the mul-
tiple branched RNA comprises sequence 5'-CCA-
CAUAAAGGGCCCACUAuuCCCACAUACUUU-
GUUGAUCC-3' (SEQ ID NO: 4). In some embodiments, 
the multiple branched RNA includes sequence 
5'-UAGUGGGCCCUUUAUGUGG-3' (SEQ ID NO: 5). In 
further embodiments, the multiple branched RNA junction 
motif is a three-branched RNA junction motif. In some 
embodiments of the present disclosure, the RNA molecules 
form dimers, trimers, hexamers, and patterned superstruc-
tures. Further, In some embodiments, a branch of the three-
branched RNA junction motif includes an a3WJ RNA 
35 siRNA is directed to Survivin, Bcl-2, XIAP, BCL-XL, or 
BRCAAl. Non-limiting examples of the siRNA include 
siRNA sequence 5' GGACCACCGCAUCUCUACAdTdT 
3' (SEQ ID NO: 7), 5' dTdTCCUGGUGGCGUAGA-
GAUGU 3' (SEQ ID NO: 8), 5'-AAGCUGuCACA-
40 GAGGGGCUAC-3' (SEQ ID NO: 9), 5'GUAGCCCCUCU-
GUGACAGCUU-3 (SEQ ID NO: 10), 
5'-CCAUGUGCUAUACAGUCAUUACUUU-3' (SEQ ID 
NO: 11 ), 5'-AAAGUAAUGACUGUAUAGCACAUGG-3' 
(SEQ ID NO: 12), 5'-UUGGACAAUGGACUGGUUGA-3' 
45 (SEQ ID NO: 13), or 5'-UCAACCAGUCCAUUGUC-
CAA-3 (SEQ ID NO: 14). In one embodiment, siRNA is a 
BRCAAl siRNA. A non-limiting example is a siRNA 
sequence 5'-CCACAUAAAGGGCCCACUA-3' (SEQ ID 
NO: 15). Another non-limiting example is a siRNA 
50 sequence 5'-UAGUGGGCCCUUUAUGUGG-3' (SEQ ID 
NO: 5). In some embodiments, the bioactive agent is a 
microRNA sequence. In some embodiments, the bioactive 
agent is an anti-miRNA molecule for a miRNA comprising 
miR-9, miR-l0b, miR-21, or miR-26. In some embodi-
55 ments, the bioactive agent is a miRNA molecule for a 
miRNA comprising let-7a, miR-l0b, miR-25, miR-34a, 
miR-124, miR-145, or miR-181b. 
As used herein, the term "subject" refers to a target of 
administration of the pharmaceutical composition. The sub-
60 ject of the herein disclosed methods can be a vertebrate, such 
as a mammal, a fish, a bird, a reptile, or an amphibian. Thus, 
the subject of the herein disclosed methods can be a human 
or non-human. Thus, veterinary therapeutic uses are pro-
vided in accordance with the presently disclosed subject 
65 matter. As such, the presently disclosed subject matter 
provides for administration to mammals such as humans and 
non-human primates, as well as those mammals of impor-
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effect, improve the therapeutic effect, 
potential in clinical tumor therapy. 
Materials and Methods 
and exhibit great 
5 Construction and Characterization of FA Conjugated 
BRCAAl-siRNA pRNA-3WJ nNnoparticles 
tance due to being endangered, such as Siberian tigers; of 
economic importance, such as animals raised on farms for 
consumption by humans; and/or animals of social impor-
tance to humans, such as animals kept as pets or in zoos. 
Examples of such animals include but are not limited to: 
carnivores such as cats and dogs; swine, including pigs, 
hogs, and wild boars; ruminants and/or ungulates such as 
cattle, oxen, sheep, giraffes, deer, goats, bison, and camels; 
rabbits, guinea pigs, and rodents. Also provided is the 
treatment of birds, including the treatment of those kinds of 10 
birds that are endangered and/or kept in zoos, as well as 
fowl, and more particularly domesticated fowl, i.e., poultry, 
such as turkeys, chickens, ducks, geese, guinea fowl, and the 
like, as they are also of economic importance to humans. 15 
Thus, also provided is the treatment of livestock, including, 
but not limited to, domesticated swine, ruminants, ungu-
lates, horses (including race horses), poultry, and the like. 




The pRNA-3WJ nanoparticle consisted of three frag-
ments, a3 wJ, b3 wJ and c3 wJ, was functionalized with folate, 
as targeting ligand; Alexa647 , as imaging module; and 
BRCAAl siRNA ( or scrambled control), as therapeutic 
module. The RNA fragments were then synthesized chemi-
cally (TriLink), self-assembled into RNAnanoparticles, and 
characterized by 1.2% agarose gel shift assays and AFM 
imaging as well as Zeta potential/Particle Sizer, as described 
previously (52). The construct contains sequences as fol-
lowing: 
Strand 1, 
(SEQ ID NO, 1) 
5' (folate)UUGCCAUGUGUAUGUGGG 3'; 
Strand 2, 
(SEQ ID NO, 4) 
5' CCACAUAAAGGGCCCACUAuuCCCACAUACUUUGUUGAUCC 3' 
Strand 3, 
(SEQ ID NO, 3) 
5' (Alexa 647)GGAUCAAUCAUGGCAA 3' 
Strand 4, 
(SEQ ID NO, 16) 
5' UAGUGGGCCCUUUAUGUGGuu 3' 
In order to evaluate the effects of a wide pH range on the 
stability of RNA nanoparticles, the prepared RNA nanopar-
ticles were dispersed in varied pH buffers for 12 h, RNA 
nanoparticles/buffer=l:l(v/v), and pH ranged from 2 to 13 
(Table 1: details of preparation of a series of buffer solu-
tions), then 1.2% agarose gel electrophoresis was used to 
characterize the stability of prepared RNA nanoparticles. 
Effects of pH on the fluorescent intensity of RNA nanopar-
Further, in some embodiments, the RNA nanoparticle 
based nano-delivery platform is expected to outperform 
treatment strategies for gastric cancer therapy in several 
aspects: (1) RNA nanoparticles have defined size, structure 
and stoichiometry. Unpredictable side effects arising from 
heterogeneous particles can thus be avoided. (2) Nanoscaled 
size of the RNA nanoparticles facilitates tissue penetration 
and target to tumor. (3) RNA nanoparticles are easy to 
construct by self-assembly, highly soluble and not prone to 
aggregation. ( 4) The RNA nanoparticles are thermodynami-
cally stable and, therefore, the entire construct will remain 
intact at ultra-low concentrations in the body. (5) The 
polyvalent nature of the RNA nanoparticle allows for easy 
integration of targeting modules, imaging modules and 
therapeutic modules into a single form. (6) RNA nanopar-
ticles display low or no immunogenicity and/or toxicity even 35 
at high doses. The 3WJ-pRNA scaffold displays favorable 
pharmacokinetic and pharmacodynamic profiles in vivo 
(half-life of 5-10 hours compared to 0.25-0.75 hours of the 
most stable 2'F modified siRNA counterparts); non-toxic; 
and no induction of interferon or cytokines. 
The presently disclosed subject matter is further illus-
trated by the following specific but non-limiting examples. 
The following examples may include compilations of data 
that are representative of data gathered at various times 
during the course of development and experimentation 45 
related to the present disclosure. 
4o ticles were investigated by measuring the fluorescent inten-
sity of RNA samples with different pH via the photolumi-
nescence (PL) spectra (Perkin Elmer LS55 
spectrofluorimeter). 
EXAMPLES 
This study reports the use of the thermostable three-way 
junction (3WJ) of bacteriophage phi29 motor pRNA to 
escort folic acid, a NIR image marker and BRCAAl siRNA 
for targeting, imaging, delivery, gene silencing and regres-
sion of gastric cancer in animal models. In vitro assay 
revealed that the RNA nanoparticles specifically bind to 
gastric cancer cells, and knock-down the BRCAAl gene. 
Apoptosis of gastric cancer cells was observed. Animal trials 
confirmed that these RNA nanoparticles could be used to 
image gastric cancer in vivo, while showing little accumu-
lation in crucial organs and tissues. The volume of gastric 
tumors noticeably decreased during the course of treatment. 
No damage to important organs by RNA nanoparticles was 
detectible. All the results indicated that this novel RNA 
nanotechnology can overcome conventional cancer thera-
peutic limitations and opens new opportunities for specific 
delivery of therapeutics to stomach cancer without damag-

















Preparation for a series of buffer solutions (pH 2 to 13) 
0.2M glycine (ml) 
5 
5 











0.2M HCl (ml) 
4.4 
1.14 
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TABLE I-continued 
Preparation for a series of buffer solutions (pH 2 to 13) 
0.05M Na2 HPO4 (ml) 0.lM NaOH (ml) 
18 
subsequent BRCAAl gene silencing effects: one harboring 
folate and BRCAAl siRNA; and, the other harboring folate 
and BRCAAl siRNA scramble control. After 48 h of treat-
ment, total RNAs from MGC803 cells were isolated by 
12* 10 5.38 




5 using Trizol (Invitrogen) and Direct-zol™ RNA MiniPrep 
(Zymo Research) according to manufacturer's instructions. 
First-strand cDNA was obtained by using 1 µg of total RNA 
and random primers and M-MLV reverse transcriptase (Pro-
mega ). All reactions were carried out in a final volume of 25 
10 µI and assayed in triplicate. qRT-PCR was performed using 
a BioRad iQ5 iCycler Detection System with a three-step 
PCR protocol (95° C. for 10 min, followed by 40 cycles of 
95° C. for 5 s, 60° C. for 30 s and 72° C. for 30 s) with 
*Glycine HCI buffer 
A.Phosphate Citrate buffer 
.&.Glycine NaOH buffer 
* Crabonate Bicarbonate buffer 
*Phosphate NaOH buffer 
•Kcl NaOH buffer 
15 
HieflTM qPCR SYBR® Green Master Mix (Yeasen). The 
data was analyzed by the llllCT method. The primers for 
BRCAAl and GAPDH are as follows: The RNAnanoparticles contained 2'-F modified U and C 
nucleotides to make them resistant to RNase degradation. 
However, Effects of RNAase A on the stability of RNA 
nanoparticles was still investigated. RNase A-free purified 
20 
water was used to dilute RNAse A (Sigma Company), the 
resulting solutions were respectively exhibited different con-
centration of RNAse A (10 U, 50 U, 100 U, 500 U, 1000 U, 
10000 U), then, each tube was respectively added into 1 µg 
RNA nanoparticles, incubated at 37° C. for 12 h, then 10% 25 
SDS-PAGE (sodium dodecylsulfate-polyacrylamide gel 
electrophoresis) gel electrophoresis is used to observe 
effects of RNAse A on the stability of RNA nanoparticles. 
The pRNA-3WJ was prepared by diluting 100 µM of the 
complexes in diethylpyrocarbonate (DEPC) treated water 30 
with PBS at 1: 1 (v/v) right before the experiments. 
Effects of Prepared RNA Nanoparticles on Cell Binding 











( SEQ ID NO, 1 7) 
(SEQ ID NO, 18) 
(SEQ ID NO, 19) 
(SEQ ID NO, 20) 
The qRT-PCR data were treated by using comparative Ct 
method, the calculation formation is as follows: 2-llllCt; 
llllCt=(treated group Ct-treated group GAPDH Ct)-(control 
group Ct-control group GAPDH Ct). The results obtained 
indicate the relative ratio is calculated that target gene 
mRNA expression levels in the treated group are divided by 
mRNA expression level in the control group. 
For western blot assays, the total cell lysates were pre-
pared in high KC! lysis buffer (10 mMTris-HCI, pH 8.0, 140 
mM NaCl, 300 mM KC!, 1 mM EDTA, 0.5% Triton X-100 
and 0.5% sodium deoxycholate) with complete protease 
The human gastric cancer MGC803 cells and human 
gastric epithelial GES-1 cells (Cell Bank of Type Culture 35 
Collection of Chinese Academy of Sciences) were main-
tained at 37° C. (5% CO2) in Dulbecco's Modified Eagle's 
Medium (DMEM, HyC!one) supplemented with 10% (v/v) 
fetal bovine serum (Gibco), 100 U/mL penicillin, and 1 
mg/mL streptomycin. Cell culture products and reagents 40 
were purchased from GIBCO. 200 nM AlexaF!uor647 
labeled 3WJ-FA-A647 was incubated with lxl05 MGC803 
and GES-1 cells at 37° C. for 1 h, after washing with PBS 
for three times, the cells were collected and resuspended in 
PBS buffer, followed by analyzed with a FACS Calibur (BD 
Biosciences). 
In order to investigate the specificity of RNA nanopar-
ticles binding to MGC803 cells, MGC 803 cells were 
cultured in a humidified 5% CO2 balanced air incubator at 
37° C. for 2 days. All the cells were collected and implanted 
onto 18 mm glass coverslips in a 12-well tissue culture plate, 
and culturing was continued for 3 days. After the cells were 
rinsed 3 times, 500 µL of medium containing prepared RNA 
nanoparticles was added into each dish and incubated for 30 
min. Three dishes of all dishes were first incubated with free 
folic acids for 30 min, then incubated with RNA nanopar-
ticles, then washed with PBS buffer, and then examined 
under the dark field microscopy. Dark-field images were 
obtained on an upright Olympus IX71 optical mi8croscope 
integrated with a CRi Nuance multispectral imaging system 60 
(Cambridge Research & Instrumentation, Inc., Woburn, 
Mass., USA). 
45 inhibitor cocktail (Roche). Thirty micrograms of protein 
were separated by SDS-PAGE and electrophoretically trans-
ferred to PVDF membranes (Millopore). The membranes 
were incubated respectively with BRCAAl antibody 
(1:2000 diluted), Bcl-2 antibody (1:2000 diluted), Rb anti-
Effects ofRNANanoparticles on the Silencing ofBRCAAl 
Gene in MGC803 Cells 
50 body (1:2000 diluted), Bax (1:2000 diluted) and ~-actin 
antibody (Epitomics) (1:4000 diluted) for overnight, fol-
lowed by 1:10000 anti-mouse secondary antibody conju-
gated with HRP (Epitomics) for 2 h. Membranes were 
blotted by Westar EtaC ECL kits (Cyanagen Sri) and 
55 exposed to film for autoradiography. 
Effects of RNA Nanoparticles on Growth and Apoptosis of 
MGC803 Cells 
Effects of prepared RNA nanoprobes on viability of 
MGC803 cells and GES-1 cells were analyzed using Cell 
Counting Kit-8 (CCK8) assay (23). MGC803 cells and 
GES-1 cells were cultured in the 96-well microplate at the 
MGC803 cells were transfected with a positive BRCAAl 65 
siRNA control using Lipofectamine 2000 (Invitrogen) as the 
carrier. Two 3WJ-RNA constructs were assayed for the 
concentration of 5000 cells per well and incubated in a 
humidified 5% CO2 balanced air incubator at 37° C. for 24 
h. Except for control wells, the remaining wells were added 
into medium with prepared RNA nanoparticles, final con-
centrations were, respectively, 10, 20, 40 and 80 µg/ml, then 
those cells were continued to culture for 24 h, 48 h and 72 
US 10,781,446 B2 
19 
h, respectively, then, the ODs were measured using the 
thermomultiskan MK3 ELISA plate reader according to the 
protocol of CCK8 assay kit, and calculated the survival rate 
of cells. The survival rate of cells can be calculated by the 
following equation: 5 
Cell viability (%)~optical density(OD) oftbe treated 
cells/OD of tbe non-treated cellsxl00 
The prepared RNA nanoparticles were incubated with 
MGC803 cells for 48 h, cell apoptosis and necrosis were 10 
determined by Annexin V-FITC/PI double staining and 
quantified by flow cytometry. Briefly, lxl05 MGC 803 cells 
were harvested 48 h after transfection and resuspended in 
100 µL binding buffer containing 5 µl annexin V-FITC and 
5 µl PI provided with the Annexin V-FITC/PI Apoptosis 15 
Detection Kit (Yeasen) for 15 min at room temperature in the 
dark. Samples were then analyzed with a F ACSCalibur (BD 
Biosciences). The live cells were identified as Annexin 
V-FITC-/PI- (lower left quadrant), early apoptotic cells as 
Annexin V-FITC+/pI- (upper left quadrant), late-stage apop- 20 
totic cells as Annexin V-FITC+/pI- (upper right quadrant), 
and necrotic cells as Annexin V-FITC-/PI+ (upper left quad-
rant). Annexin V-FITC/PI Apoptosis Detection Kit was 
purchased from Yeasen Corporation (Shanghai, China). 
RNA Nanoparticles for NIR Fluorescent Imaging ofln Vivo 25 
Gastric Cancer 
Female athymic nude mice (18-22 g) were purchased 
from Shanghai Slac Laboratoty Animal Co. Ltd (Shanghai, 
China). For the establishment of tumor model, MGC803 
cells were resuspended in PBS and 2xl06 cells/site was 30 
subcutaneously injected in the right flank. When the tumor 
nodules had reached a volume of 0.1-0.3 cm3 after approxi-
mately 3 weeks post-injection, mice were used for biodis-
tribution and imaging studies. For tumor imaging, FA-Alexa 
Fluor 647-labeled pRNA-3WJ nanoparticle (about 20 nmol 35 
in PBS buffer, equal 32 mg/kg) was administrated intrave-
nously into the MGC-803-tumour-bearing mice. Time-
course fluorescent images ( excitation: 630/20 nm, emission: 
700/30 nm, integration time: 15 s) were acquired on a 
Bruker In-Vivo F PRO imaging system (Billerica, Mass.). 40 
All the post injection images were captured at the same 
parameter setting and are scaled to the same maximum 
values. For the ex vivo imaging, the mice (3 mice per time 
point) were then sacrificed and collected tumors and the 
major organs after 3, 24,48, 96 h and 7 day intravenously 45 
(iv) injection. Excised tumor and organs were imaged by the 
Bruker In-Vivo F PRO imaging system with the same 
parameters as mentioned above. 
20 
by hematoxylin and eosin (HE) stain method, and were 
observed by microscopy to confirm whether there is patho-
logical lesion in important organs existed. 
Statistical Analysis 
Each experiment was repeated three times in duplicate. 
The results were presented as mean±SD. Statistical differ-
ences were evaluated using the t-test and considered sig-
nificance at P<0.05. 
Results 
Construction and Characterization of Triple-Functional 
pRNA-3WJ Nanoparticles 
The pRNA-3WJ nanoparticles were prepared by mixing 
the three strands a3 wJ, b3 wJ, and c3 wJ respectively, at equal 
molar ratio (FIG. la). Atomic force microscopy (AFM) 
image highly suggested the formation of homogeneous 
triangular branched architectures, confirming that pRNA-
3WJ nanoparticles were successfully prepared (FIG. lb). 
Regarding the RNA nanoparticles' size and surface charge, 
the dynamic light scattering experiments showed that the 
size of the nanoparticle is 5.20±0.83 nm in diameter, and the 
zeta potential is -16.57±0.75 my, as shown in FIGS. 12A 
and 12B. 
In order to evaluate the effects of a wide pH range on the 
stability of RNA nanoparticles, the prepared RNA nanopar-
ticles were dispersed in varied pH buffers (RNA nanopar-
ticles/buffer= 1: l(v/v)) for 12 h. The details of the prepara-
tion of a series of buffer solutions with pH 2 to 13 were 
shown in Table 1. The effects of pH on the fluorescent 
intensity of RNA nanoparticles is investigated. As shown in 
FIG. 13A, in the range of pH 2 to 13, RNA nanoparticles 
exhibited different fluorescent intensity, and in the range of 
pH 5-9, RNA nanoparticles displayed more than 90% strong 
fluorescent signals. The study used 1.2% agarose gel elec-
trophoresis to characterize the stability of prepared RNA 
nanoparticles. As shown in FIG. 13B, tested RNA nanopar-
ticles displayed identical position and similar brightness on 
the gel, no degradation, suggesting that the RNA nanopar-
ticles are stable in the range of pH 2 to 13. 
The melting temperature of the 3WJ-BRCAA1 siRNA 
nanoparticle was determined as 69.2±0.9° C. by real-time 
PCR, as shown in FIG. 14. Melting experiments were 
conducted by monitoring the fluorescence of the RNA 
nanoparticles or the assembly intermediates using the Light-
Cycler 480 Real-Time PCR System (Roche). lxSYBR 
Green dye was used for all the experiments. The RNA 
samples were dissolved in lxTMS buffer and slowly cooled 
from 95 to 20° C. The melting temperature of the 3WJ-
BRCAA1 siRNA nanoparticle was determined as 69.2±0.9° 
C. The data represents the mean and standard deviation of RNA Nanoparticles for Targeted Therapy of In Vivo Gastric 
Cancer 50 three independent experiments. 
Nude mice loaded with gastric cancer MGC803 cells were 
prepared according to the previous reports (12-15), and were 
randomly divided into three groups: test group (10 mice) 
(FA-pRNA-3WJ-BRCAAlsiRNA, 1 mg/kg body weight); 
control group (10 mice) (FA-pRNA-3WJ-Scram siRNA, 1 55 
mg/kg body weight) and blank control (10 mice) (untreated). 
When the tumor sizes reached about 5 mm in diameter, the 
nude mice were injected with prepared RNA nanoparticles 
in PBS via tail vein (1 mg/kg body weight). Every two days, 
the tumor volume was measured, up to 15 days. Then, these 60 
mice were sacrificed. 
Effects of RNA Nanoparticles on Important Organs 
The mice in testing group were sacrificed after being 
raised for 15 days. For histological evaluation, excised 
important organs including heart, liver, spleen, lung and 65 
kidney were frozen and embedded by medium at -20° C., 
and then were sectioned into 8 µm slices, then were stained 
Effects of RNAase A on the stability of RNA nanopar-
ticles were also investigated. RNase A-free purified water 
was used to dilute RNAse A (Sigma Company). The result-
ing solutions were respectively exhibited different concen-
tration of RNAse A (10 U, 50 U, 100 U, 500 U, 1000 U, 
l0000U). Then each tube was respectively added l □g RNA 
nanoparticles, incubated at 37° C. for 12 h, and finally 10% 
SDS-PAGE gel electrophoresis was used to examine the 
effects of RN Ase A on the stability of RNA nanoparticles. As 
shown in FIG. 15, RNA nanoparticles on different lanes 
exhibited identical position, similar brightness, no obvious 
degradation, which highly suggests that prepared RNA 
nanoparticles own good stability against RNase A (less than 
10000 U) degradation. 
The resultant pRNA-3WJ nanoparticles are thermody-
namically and chemically stable, which makes them an 
attractive candidate for in vivo nano-delivery for the purpose 
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of cancer detection or treatment. In this study, folate is 
incorporated, as targeting ligand; Alexa647 , as imaging mod-
ule; and BRCAAl siRNA ( or scrambled control) into the 
pRNA-3WJ scaffold. 
Binding Efficiency of pRNA Nanoparticles to Gastric Can- 5 
cer Cell 
Flow cytometry data in FIG. 2 showed that the prepared 
3WJ-FA-A647 nanoparticles can bind with the MGC803 
cells with almost 100% binding efficiency, while the GES-1 
cells display a weak signal, which highly suggested that the 10 
prepared RNA nanoparticles did not bind with GES-1 cells. 
Results also demonstrate that folic acid receptor exhibits 
over-expression on the surface ofMGC803 cells, no expres-
sion on the surface of GES-1 cells, similar to a previous 15 
report (15). 
Effects of RNA Nanoparticles on the Silence of BRCAAl 
gene in MGC803 Cells 
The qRT-PCR results in FIG. 3a showed that, prepared 
FA-pRNA-3WJ-BRCAA1 siRNA nanoparticles could 20 
silence expression ofBRCAAl gene in MGC803 cells after 
incubating with MGC803 cells for 48 h, in contrast, pre-
pared FA-pRNA-3WJ-Scram siRNAnanoparticles could not 
silence expression ofBRCAAl gene in MGC803 cells after 
incubation for 48 h, between two groups, there existed 25 
statistical difference (P<0.01). Compared with BRCAAl 
siRNA, prepared FA-pRNA-3WJ-BRCAA1 siRNA nano-
particles achieved similar silencing efficiency of BRCAAl 
gene in MGC803 cells. The Ct, Delta Ct, and Delta Delta Ct 
values for the qRT-PCR assay are shown in Table 2. Addi- 30 
tionally, as shown in FIG. 3b, Western blotting results 
further confirmed that prepared FA-pRNA-3WJ-BRCAA1 
siRNA nanoparticles and BRCAAl siRNA could down-
regulate BRCAAl expression in MGC803 cells, while pre-
35 
pared FA-pRNA-3WJ-Scram siRNAnanoparticles had little 
down-regulation of BRCAAl protein expression in 
MGC803 cells, thus showing prepared FA-pRNA-3WJ-
BRCAA1 siRNA nanoparticles can specifically silence 
expression of BRCAAl protein in MGC803 cells. Impor-
40 
tantly, the silencing potency was comparable to the Lipo-
fectamine 2000 carried BRCAAl siRNA group. 
TABLE S2 
The expression levels of BRCAAl normalized to the exogenous 
GAPDH mRNA in the treated group and control group (the 
Ct, Delta Ct, and Delta Delta Ct values). 
group Ct LI.Ct LI.LI.Ct 2~veMCt P value 
GAPDH 6.943 
BRCAAl-siRNA 14.931 7.988 1.435 0.485 0.005 
FA-pRNA-3WJ-Scramb- 20.566 13.623 4.427 0.051 0.001 
siRNA 
GAPDH 6.944 
FA-pRNA-3WJ- 15.194 8.252 1.507 0.404 0.000 
BRCAAl-siRNA 
GAPDH 6.942 
Effects of RNA Nanoparticles on Growth and Apoptosis of 





Previous study shows that BRCAAl can inhibit MGC803 
cell apoptosis and improve the proliferation of MGC803 
cells, it is hypothesized that the performed RNA interference 
(RNAi) by RNA nanoparticles could induce MGC803 cell 
apoptosis. As shown in FIG. 5, the transfection with 25 nM 
FA-pRNA-3WJ-BRCAA1 siRNAin MGC803 cells induced 
2.51% of early apoptotic cells and 15.0% of late apoptotic 
cells, respectively, in the normal control, MGC803 cells 
exhibited 0.085% of early apoptotic cells, there existed 
statistical difference between treated group with FA-pRNA-
3WJ-BRCAA1 siRNA and control group, P<0.05. The light 
scattering plot of MGC 803 cells treated with FA-pRNA-
3WJ-BRCAA1 siRNA nanoparticles for 48 his shown in 
FIG. 16. These results show that prepared FA-pRNA-3WJ-
BRCAA1 siRNA nanoparticles can induce apoptosis of 
MGC803 cells. 
Fluorescent RNA Nanoparticles for In Vivo Imaging of 
Gastric Cancer 
It has been reported that unmodified siRNA ribonucleic 
acid sequences have extremely poor pharmacokinetic prop-
erties due to short in vivo half-life and fast kidney clearance 
caused by their small size (hydrodynamic diameters, HDs; 
typically <5 nm, which is smaller than the kidney filtration 
threshold (KFT) of 5.5 nm). Tumor targeting efficiency by 
RNA nanoparticles was investigated by collecting and ana-
lyzing in situ fluorescence images of MGC803 xenografts in 
nude mice at different post-injection (p.i.) time points (FIGS. 
6a and c ). Tumor area was hardly distinguished in the mouse 
in the first 30 min p.i. because of the strong fluorescence 
background in normal tissues. However, as the time 
increased, the decrease in the fluorescence background of 
normal tissues and the accumulations at the tumor site 
caused the tumor area became readily defined 5 h p.i. Ex 
vivo images of normal tissues, organs, and tumors taken 
from the RNA nanoparticles-injected mice showed that the 
tumors taken at 5 and 24 h p.i. exhibited the strongest signal 
(FIG. 6b). In terms of tumor accumulation kinetics, RNA 
nanoparticles reached their highest accumulation within 5 h 
and remained in the tumor site 96 h p.i., which indicted the 
high tumor targeting efficiency and tumor retention capabil-
ity of the constructed RNA nanoparticles. 
RNA Nanoparticles for In Vivo Targeted Therapy of siRNA 
to Gastric Cancer 
As shown in FIGS. 7 and 8, the tumor in the mouse 
without treatment grew very rapidly, the size of tumor 
enlarged as a control. In contrast, the tumor in mice with 
treatment showed regressed growth and the size of tumor is 
smaller comparing to controls. The difference between 
FA-pRNA-3WJ-BRCAAlsiRNA treated group and 
FA-pRNA-3WJ-Scram-siRNA treated group was statisti-
cally different (P<0.01). The result fully demonstrated that 
prepared FA-pRNA-3WJ-BRCAA1 siRNA nanoparticles 
can specifically inhibit the growth of gastric cancer cells in 
VIVO. 
Undetectable of Organ Damage by RNA Nanoparticles after 
Systemic Injection. 
Harris Hematoxylin and Eosin (HE) staining are used to 
check the potential damage to important organs including 
the heart, liver, spleen, lung and kidney by the RNA nano-
As shown in FIG. 4, MGC 803 cells were treated with 400 
µg/mL FA-pRNA-3WJ-BRCAA1 siRNA nanoparticles for 
60 particles. As shown in FIG. 9, no obvious tissue damages 
were observed, which indirectly suggested that the prepared 
RNA nanoparticles displayed good biocompatibility and no 
negative effects on important organs in the body was 
observed. 
24 h, 48 h and 72 h, the inhibition rate of MGC 803 cells 
increased as the incubation time increased, at 48 h, maximal 
inhibition rate of MGC803 cells is 44.5±2.6%, compared 
with FA-pRNA-3WJ-Scram siRNA group, inhibition rate is 65 
12.5±1.9%, there existed statistical difference between two 
groups, P<0.01. 
In this study, in order to investigate the feasibility of 
applying RNAnanoparticles as theranostic agents for gastric 
cancer diagnosis and therapy, the pRNA-3WJ nanoparticle 
US 10,781,446 B2 
23 
is designed consisting of three fragments, a3 wJ, b3 wJ and 
c3 wJ, and functionalized with folate, as targeting ligand; 
Alexa647, as imaging module; and BRCAAl siRNA (or 
scrambled control), as therapeutic module, respectively. 
FA-pRNA-3WJ-BRCAA1 siRNA nanoparticles is prepared 5 
and the resulting RNA nanoparticles showed good pH and 
thermodynamic stability, good stability against RNase A 
(less than 10000 U) degradation, and exhibited stability of 
fluorescent intensity. These results demonstrated that the 
prepared RNA nanoparticles should be very stable in the 10 
blood circulation and can act as high efficient theranostic 
agent for targeted imaging and siRNA therapy of gastric 
cancer in vivo, which lay foundation for RNAnanoparticles' 
further clinical application. 
Nanotoxicity of nanotheranostic agents has caused broad 15 
attention. In this study, prepared RNA nanoparticles did not 
exhibit obvious toxicity. After being injected into in vivo 
blood circulation via tail vain, RNA nanoparticles gradually 
accumulated in the site of in vivo tumor within 6 h p.i., 
clearly displayed the imaging of tumor tissues, and exhibited 20 
specific targeting ability. The RNA nanoparticles were also 
proved to be able to retention in the tumor for long time and 
generate tumor regression effects. 
In addition, the alteration of biochemical parameters in 
the mice after treating with FA-pRNA-3WJ-BRCAA1 25 
siRNA nanoparticles was investigated as shown in Table 3 
and o obvious tissue damages were observed for liver and 
kidneys. To study the effects ofRNAnanoparticles on blood 
biochemical parameters, blood samples were centrifuged 
twice at 3000 rpm for 10 min. Liver function was evaluated 30 
with serum levels of alanine aminotransferase (ALT), aspar-
tate aminotransferase (AST). Nephrotoxicity was deter-
mined by blood urea nitrogen (BUN) and creatinine (Cr). 
These parameters were all assayed using a Hitachi 7600 
Automatic Biochemical Autoanalyzer. 35 
TABLE S3 
Blood biochemical examination results 
40 
WBC AST ALT Cr UN 
FA-pRNA-3WJ-
BRCAAl -siRNA NPs 
20 µg 4.3 X 105 32 35 0.005 0.041 
1 day 
45 
7 day 4.2 X 105 33 35 0.005 0.042 
14 day 4.4 X 105 33 35 0.006 0.043 
60 µg 5.2 X 105 35 42 0.007 0.038 
1 day 
7 day 4.9 X 105 33 42 0.004 0.039 
14 day 4.5 X 105 34 42 0.005 0.039 50 
FA-pRNA-3WJ-
Scramb-siRNA 
20 µg 4.2 X 105 32 36 0.004 0.052 
1 day 
7 day 4.2 X 105 34 37 0.002 0.054 55 
14 day 4.2 X 105 35 38 
60 µg 4.2 X 105 32 34 0.031 0.045 
1 day 
7 day 4.2 X 105 33 35 0.036 0.037 
14 day 4.2 X 105 35 37 0.034 0.038 
Control 60 
0 3.9 X 105 28 32 0.001 0.008 
Further HE staining results also confirmed that prepared 
RNA nanoparticles did not damage important organs such as 
brain, heart, lungs, liver and kidneys. Therefore, it can be 65 
confirmed that the prepared RNA nanoparticles should be 
safe for in vivo application. 
24 
In this study, the results of in vivo evaluation of thera-
peutic efficacy also showed that the prepared RNA nano-
particles can actively target in vivo gastric cancer tissues and 
inhibited tumor growth significantly. However, the concrete 
molecular mechanism is not well understood. In order to 
investigate the potential molecular mechanism, Western 
blotting is used to detect the expression level of BRCAAl, 
Bcl-2, Rb and Bax in MGC803 cells treated with prepared 
RNA nanoparticles for 24 hand 48 h. As shown in FIG. 10, 
RNA nanoparticles can down-regulate or silence the expres-
sion of BRCAAl gene, down-regulate expression of Bcl-2 
gene, adversely up-regulate expression of Rb and Bax genes 
in MGC803 cells. Based on these results, a molecular 
mechanism of RNA nanoparticle induced MGC803 growth 
inhibition is studied: the prepared RNA nanoparticles (FA-
pRNA-3WJ-BRCAA1 siRNA) actively bind to the folic acid 
receptor on the surface of MGC803 cells via folic acids 
conjugated on the RNA nanoparticles, and then induce the 
endocytosis of RNA nanoparticles into tumor cytoplasm. 
The double-stranded BRCAAl siRNA region on the RNA 
nanoparticle can be recognized by RNA-induced silencing 
complex (RISC) in the cytoplasm and processed. The 
released siRNA antisense strand can further recognize target 
BRCAAl mRNA, degrade it, and result in silence of 
BRCAAl gene in MGC803 cells. The down regulate or 
silencing of the BRCAAl gene will cause subsequent down-
regulation of Bcl-2 gene, and further up-regulation of Rb 
and Bax gene, which will end up with inducing cell apop-
tosis and inhibiting the cell growth. The proposed mecha-
nism is summarized in FIG. 11 and the concrete study of the 
regulation signal pathway is under way. 
In recent years, BRCAAl gene, as an important member 
of ARID family, called as ARID4B, has been found to 
involve in the regulation of the male fertility and stem cells, 
ARID4B protein can regulate Rb binding protein 1, which 
highly suggest that ARID4B may be a tumor suppressor. 
Throughout this document, various references are men-
tioned. All such references are incorporated herein by ref-
erence, including the references set forth in the following 
list. 
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<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 1 
uugccaugug uauguggg 
<210> SEQ ID NO 2 
<211> LENGTH, 20 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 2 
cccacauacu uuguugaucc 
<210> SEQ ID NO 3 
<211> LENGTH, 16 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 3 
ggaucaauca uggcaa 
<210> SEQ ID NO 4 
<211> LENGTH, 41 





<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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-continued 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 4 
ccacauaaag ggcccacuau ucccacauac uuuguugauc c 
<210> SEQ ID NO 5 
<211> LENGTH, 19 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 5 
uagugggccc uuuaugugg 
<210> SEQ ID NO 6 
<211> LENGTH, 39 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 6 
gccuuaguaa cgugcuuuga ugucgauucg acaggaggc 
<210> SEQ ID NO 7 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Combined DNA/RNA Molecule, 
Synthetic oligonucleotide 
<400> SEQUENCE, 7 
ggaccaccgc aucucuacat t 
<210> SEQ ID NO 8 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Combined DNA/RNA Molecule, 
Synthetic oligonucleotide 
<400> SEQUENCE, 8 
ttccuggugg cguagagaug u 
<210> SEQ ID NO 9 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 9 








<210> SEQ ID NO 10 
<211> LENGTH, 21 
<212> TYPE, RNA 
31 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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-continued 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 10 
guagccccuc ugugacagcu u 
<210> SEQ ID NO 11 
<211> LENGTH, 25 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 11 
ccaugugcua uacagucauu acuuu 
<210> SEQ ID NO 12 
<211> LENGTH, 25 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 12 
aaaguaauga cuguauagca caugg 
<210> SEQ ID NO 13 
<211> LENGTH, 20 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 13 
uuggacaaug gacugguuga 
<210> SEQ ID NO 14 
<211> LENGTH, 20 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 14 
ucaaccaguc cauuguccaa 
<210> SEQ ID NO 15 
<211> LENGTH, 19 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 









<210> SEQ ID NO 16 
<211> LENGTH, 21 
<212> TYPE, RNA 
33 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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-continued 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 16 
uagugggccc uuuauguggu u 
<210> SEQ ID NO 17 
<211> LENGTH, 18 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 17 
accaaatctc ccgcaagg 
<210> SEQ ID NO 18 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 18 
catattttcc aggtccgaca 
<210> SEQ ID NO 19 
<211> LENGTH, 19 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 19 
gaaggtgaag gtcggagtc 
<210> SEQ ID NO 20 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
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What is claimed is: 
1. An artificial RNA nano structure molecule, comprising: 
a multiple branched RNA junction motif comprising at least 
one RNA oligonucleotide, and a gastric cancer targeting 
module coupled to the RNA junction motif, wherein the 5 
multiple branched RNA comprises sequence 5' 
UAGUGGGCCCUUUAUGUGG 3' (SEQ ID NO: 5). 
2. The molecule of claim 1, further comprising at least one 
bioactive agent coupled to the RNA junction motif. 
3. The molecule of claim 2, wherein the bioactive agent 10 
comprises a an siRNA, an miRNA, an anti-mRNA, a 
ribozyme RNAs, an antisense RNA, or a combination 
thereof. 
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12. The molecule of claim 1, wherein the multiple 
branched RNA junction motif is a three-branched RNA 
junction motif. 
13. The molecule of claim 12, wherein the three-branched 
RNA junction motif comprises an a3 WJ RNA module (SEQ 
ID NO: 1); a b3WJ RNA module (SEQ ID NO: 2); a c3WJ 
RNA module (SEQ ID NO: 3), or any combination thereof. 
14. The molecule of claim 1, wherein the diameter of the 
molecule is at least about 40 nm or less. 
15. The molecule of claim 1, wherein the molecule has 
zeta potential ranging from about -150 m V to about 150 m V. 
16. The molecule of claim 1, wherein the molecule is 
substantially stable in a pH value ranges from about 2 to 
about 13. 
4. The molecule of claim 3, wherein the siRNA is directed 
to Survivin, Bcl-2, XIAP, BCL-XL, or BRCAAl. 
17. The molecule of claim 1, wherein the gastric cancer 
15 targeting module comprises a ligand that binds to at least one 
gastric cancer cell surface marker. 
5. The molecule of claim 3, wherein the bioactive agent 
comprises siRNA sequence 5' GGACCACCGCAUCUC-
UACAdTdT 3' (SEQ ID NO: 7), 5' dTdTCCUGGUG-
GCGUAGAGAUGU 3' (SEQ ID NO: 8), 5'-AAGCUGu-
CACAGAGGGGCUAC-3' (SEQ ID NO: 9), 
5'GUAGCCCCUCUGUGACAGCUU-3 (SEQ ID NO: 10), 
5'-CCAUGUGCUAUACAGUCAUUACUUU-3' (SEQ ID 
NO: 11 ), 5'-AAAGUAAUGACUGUAUAGCACAUGG-3' 
(SEQ ID NO: 12), 5'-UUGGACAAUGGACUGGUUGA-3' 25 
(SEQ ID NO: 13), 5'-UCAACCAGUCCAUUGUCCAA-3 
(SEQ ID NO: 14), 5'-CCACAUAAAGGGCCCACUA-3' 
(SEQ ID NO: 15), 5'-UAGUGGGCCCUUUAUGUGG-3' 
(SEQ ID NO: 5). 
18. The molecule of claim 17, wherein the ligand binds to 
a folate receptor, an epidermal growth factor receptor 2 
(ErbB-2/HER2), an epidermal growth factor receptor 
20 (EGFR), a HER2 or a combination thereof. 
19. The molecule of claim 18, wherein the targeting 
module is a folate. 
20. The molecule of claim 17, wherein the ligand is an 
aptamer. 
21. The molecule of claim 20, wherein the aptamer binds 
to EGFR, PDGFR, folate receptor, or a combination thereof. 
22. The molecule of claim 21, wherein the ligand has 
sequence 5'-G CCU UAG UAA CGU GCU UUG AUG 
UCG AUU CGA CAG GAG GC-3' (SEQ ID NO: 6). 
6. The molecule of claim 3, wherein the bioactive agent 30 
is an anti-miRNAmolecule for a miRNAcomprising miR-9, 
miR-l0b, miR-21, or miR-26. 
23. A composition comprising the artificial RNA nano-
structure molecule of claim 1 and a pharmaceutically accept-
able carrier. 
24. A nanoparticle delivery system, comprising the arti-
ficial RNA nano structure of claim 1 and a pharmaceutically 
acceptable carrier. 
7. The molecule of claim 3, wherein the bioactive agent 
is a miRNA molecule for a miRNA comprising let-7a, 
miR-l0b, miR-25, miR-34a, miR-124, miR-145, or miR- 35 
181b. 25. A method of treating gastric cancer in a subject having 
gastric cancer, comprising administering to the subject a 
therapeutically effective amount of a composition compris-
ing the artificial RNA nanostructure of claim 1 and a 
8. The molecule of claim 2, wherein the bioactive agent 
comprises a drug, a fluorescent dye, a chemical, or a 
combination thereof. 
9. The molecule of claim 2, wherein the bioactive agent 
is directed a gastric cancer marker. 
10. The molecule of claim 1, wherein the nanostructure 
comprises at least one chemical modification at 2' position, 
wherein the chemical modification comprises 2' Fluoro, 2' 
Amine, and 2' 0-Methyl. 
11. The molecule of claim 1, wherein the multiple 
branched RNA further comprises sequence 5' CCA-
CAUAAAGGGCCCACUAuuCCCACAUACUUU-
GUUGAUCC 3' (SEQ ID NO: 4). 
40 pharmaceutically acceptable carrier. 
26. An artificial RNA nanostructure molecule, compris-
ing: a multiple branched RNA junction motif comprising at 
least one RNA oligonucleotide, and a gastric cancer target-
ing module coupled to the RNA junction motif, further 
45 comprising at least one bioactive agent coupled to the RNA 
junction motif, wherein the bioactive agent comprises 
siRNA sequence 5'-UAGUGGGCCCUUUAUGUGG-3' 
(SEQ ID NO: 5). 
* * * * * 
